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AbstrACt
background The programmed cell death-1/programmed 
cell death ligand-1 (PD-1/PD- L1) axis plays a central role 
in suppressing antitumor immunity; axis dysregulation 
can be used by cancer cells to evade the immune system. 
Tislelizumab, an investigational monoclonal antibody 
with high affinity and binding specificity for PD-1, was 
engineered to minimize binding to FcγR on macrophages 
to limit antibody- dependent phagocytosis, a potential 
mechanism of resistance to anti- PD-1 therapy. The aim 
of this phase IA/IB study was to investigate the safety/
tolerability, antitumor effects and optimal dose and 
schedule of tislelizumab in patients with advanced solid 
tumors.
Methods Patients (aged ≥18 years) enrolled in phase 
IA received intravenous tislelizumab 0.5, 2, 5 or 10 mg/
kg every 2 weeks; 2 or 5 mg/kg administered every 
2 weeks or every 3 weeks; or 200 mg every 3 weeks; 
patients in phase IB received 5 mg/kg every 3 weeks. 
Primary objectives were to assess tislelizumab’s safety/
tolerability profile by adverse event (AE) monitoring and 
antitumor activity using RECIST V.1.1. PD- L1 expression 
was assessed retrospectively with the VENTANA PD- L1 
(SP263) Assay.
results Between May 2015 and October 2017, 451 
patients (n=116, IA; n=335, IB) were enrolled. Fatigue 
(28%), nausea (25%) and decreased appetite (20%) were 
the most commonly reported AEs. Most AEs were grade 
1–2 severity; anemia (4.9%) was the most common grade 
3–4 AE. Treatment- related AEs led to discontinuation 
in 5.3% of patients. Grade 5 AEs were reported in 14 
patients; 2 were considered related to tislelizumab. 
Pneumonitis (2%) and colitis (1%) were the most common 
serious tislelizumab- related AEs. As of May 2019, 18% 
of patients achieved a confirmed objective response in 
phase IA and 12% in phase IB; median follow- up duration 
was 13.6 and 7.6 months, respectively. Pharmacokinetics, 
safety and antitumor activity obtained from both phase IA 
and IB determined the tislelizumab recommended dose; 
ultimately, tislelizumab 200 mg intravenous every 3 weeks 
was the dose and schedule recommended to be taken into 
subsequent clinical trials.
Conclusions Tislelizumab monotherapy demonstrated an 
acceptable safety/tolerability profile. Durable responses 
were observed in heavily pretreated patients with 
advanced solid tumors, supporting the evaluation of 
tislelizumab 200 mg every 3 weeks, as monotherapy and in 
combination therapy, for the treatment of solid tumors and 
hematological malignancies.
trial registration number NCT02407990.
IntroduCtIon
The programmed cell death-1/programmed 
cell death ligand-1 (PD-1/PD- L1) axis plays 
a central role in suppressing antitumor 
immunity; dysregulation of the PD-1/PD- L1 
axis can be used by cancer cells to evade the 
immune system.1 2 PD- L1 is an immune check-
point protein that is often overexpressed on 
the surface of tumor and immune cells in 
the tumor microenvironment.3 4 PD-1, the 
cell receptor for PD- L1, is mainly expressed 
in activated T cells.5 An increase in PD-1 
expression in the tumor microenvironment 
has been reported in many cancer types.6–8 
Increased expression of PD-1 and PD- L1 is 
often associated with poor survival but may 
be predictive of anti- PD-1/PD- L1 antitumor 
activity.9–11
Tislelizumab is an investigational human-
ized IgG4 monoclonal antibody with high 
affinity and binding specificity for PD-1.12 
Tislelizumab was engineered to minimize 
binding to FcγR on macrophages in order 
to limit antibody- dependent phagocytosis, 
a potential mechanism of resistance to anti- 
PD-1 therapy.1 Preclinical data suggest tisleli-
zumab does not bind to FcγRI, whereas 
other anti- PD-1 antibodies bind to FcγRI in a 
manner consistent with human IgG4 antibody 
affinity.12 Furthermore, in cell- based assays, 
tislelizumab enhanced the functional activity 
of human T cells and pre- activated primary 
peripheral blood mononuclear cells.12
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PHASE IA, PART 1
Dose Escalations
PHASE IB: Indication Expansion
PHASE IA, PART 2
Schedule Expansion*
PHASE IA, PART 3
Fixed Dose Expansion†‡
0.5 mg/kg Q2W, n=3 2 mg/kg Q2W, n=20
2 mg/kg Q2W, n=6 2 mg/kg Q3W, n=21
5 mg/kg Q2W, n=6 5 mg/kg Q2W, n=20
10 mg/kg Q2W, n=7 5 mg/kg Q3W, n=20
200 mg Q3W
n=13
KEY
OBJECTIVES
PHASE IA
Safety,
RP2D, and 
preliminary 
efficacy
PHASE IB
Efficacy and 
safety in 
multiple
tumor types 
Expansion in ~330 patients with multiple tumor types
ARM 1: n=50 ARM 2: n=20 ARM 3: n=50
ARM 5: n=20 ARM 6: n=50
ARM 9: n=50
ARM 7: n=20 ARM 8: n=20
Non-small cell 
lung cancer Ovarian cancer Gastric cancer
ARM 4: n=50
Hepatocellular 
carcinoma
Esophageal carcinomaHead and neck squamous cell carcinoma
Triple-negative
breast cancer Cholangiocarcinoma
Renal cell carcinoma, urothelial cancer, melanoma, Merkel cell carcinoma, sarcoma, gastrointestinal stromal tumor, or
cutaneous squamous cell carcinoma. Or any other metastatic microsatellite instability-high or mismatch repair deficient solid 
tumors, such as CRC or pancreatic cancer
 5 mg/kg Q3W
Figure 1 Study design. CRC, colorectal cancer; Q3W, every 3 weeks.
This first- in- human (FIH), dose- escalation/dose- 
expansion study assessed the safety/tolerability, pharma-
cology and clinical activity of tislelizumab in patients with 
advanced solid tumors. The primary objective was to eval-
uate the safety and tolerability of tislelizumab (phase IA), 
as well as the antitumor response (phase IB). Secondary 
end points included determining the maximum toler-
ated dose (MTD) and the optimal dose and treatment 
regimen. Confirmed objective response rate (ORR) to 
tislelizumab by PD- L1 status was an exploratory end point.
Methods
study design and treatment administration
The design of this phase IA/IB study is detailed in 
figure 1. Phase IA comprised three parts. Part 1 was a 
dose- escalation/dose- finding phase that followed a modi-
fied 3+3 design. Four weight- based dose levels (0.5, 2, 
5 and 10 mg/kg every 2 weeks) were assessed for dose- 
limiting toxicity (DLT). If a DLT was observed in the first 
three patients completing one cycle of treatment at a 
given dose level, three additional patients were enrolled. 
A DLT was defined as an adverse event (AE) occurring 
in the first 28- day cycle that met the predefined criteria 
based on grading per NCI- CTCAE V.4.03. DLT criteria 
included any grade ≥4 non- hematological toxicity or 
grade 4 laboratory anomaly irrespective of duration; 
any grade ≥3 immune- related AE (irAE), grade 3 tumor 
flare (ie, local pain, irritation or rash localized at sites of 
known/suspected tumor) for >7 days; grade 3 AEs irre-
spective of duration, except for laboratory abnormalities, 
diarrhea, nausea and vomiting; asymptomatic biochem-
ical abnormalities that improve to grade ≤2 within 3 days 
of institution of supportive care and grade 2 ophthalmo-
logical toxicities. Hematological toxicities meeting DLT 
criteria include febrile neutropenia (defined as absolute 
neutrophil count <1000/mm3 with a single temperature 
of 38.3°C or a sustained temperature of 38°C for >1 hour); 
grade 4 thrombocytopenia, grade 4 anemia or grade 4 
neutropenia lasting >7 days; grade 3 thrombocytopenia 
with bleeding and grade 3 neutropenic infection. No 
additional patients were required if a DLT was observed 
in one of six patients. Dose escalation continued until 
two out of six patients in each dose cohort experienced a 
DLT. If an MTD could not be established after evaluation 
of all planned doses, then the dose for subsequent studies 
would be determined based on safety and pharmacoki-
netic (PK) profile from aggregated data across the study. 
Part 2 of phase IA was a schedule expansion that evaluated 
tislelizumab at 2 and 5 mg/kg every 2 weeks and every 3 
weeks. Part 3 of phase IA (fixed- dose expansion) evalu-
ated tislelizumab 200 mg administered every 3 weeks. The 
phase IB component of this study was an expansion phase 
of tislelizumab at 5 mg/kg every 3 weeks in nine disease- 
specific cohorts. The initial administration of tislelizumab 
was administered via a 60 min infusion, if tolerated, the 
infusion was shortened to 30 min for all subsequent 
administrations. Dose modifications/delays were allowed; 
criteria for dose modifications are presented on page 2 of 
the online supplementary appendix.
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Table 1 Patient demographics and baseline disease characteristics
Phase IA
(n=116)
Phase IB
(n=335)
Overall
(n=451)
Age (median years)* 60.5 (19.0 to 80.0) 61.0 (18.0 to 81.0) 61.0 (18.0 to 81.0)
Sex
  Male 55 (47.4) 191 (57.0) 246 (54.5)
  Female 61 (52.6) 144 (43.0) 205 (45.5)
Race
  Asian 10 (8.6) 120 (35.8) 130 (28.8)
  African- American 0 (0.0) 5 (1.5) 5 (1.1)
  Caucasian 101 (87.1) 189 (56.4) 290 (64.3)
  Other 5 (4.3) 18 (5.4) 26 (5.7)
ECOG performance status
  0 56 (48.3) 113 (33.7) 169 (37.5)
  1 60 (51.7) 222 (66.3) 282 (62.5)
Number of prior systemic drug therapy†
  0‡ 18 (16.4) 50 (15.6) 68 (15.8)
  1 33 (30.0) 119 (37.2) 152 (35.3)
  2 22 (20.0) 77 (24.1) 99 (23.0)
  ≥3 37 (33.6) 74 (23.1) 111 (25.8)
Prior radiotherapy 63 (54.3) 178 (53.1) 241 (53.4)
Prior anticancer surgery 100 (86.2) 223 (66.6) 323 (71.6)
Data presented as n (%), except where noted.
*Data presented as median (range).
†Only therapy used for metastatic, locally advanced or palliative is counted as a line of systemic therapy. The ‘n’ is number of patients with 
any line of prior systemic therapies.
‡Patients may have received adjuvant and/or neoadjuvant therapies.
ECOG, Eastern Cooperative Oncology Group.
Approximately 120 patients were planned to be enrolled 
in phase IA. Twenty- four patients were needed for part 1, 
and ~20 patients were planned for the schedule- expansion 
and fixed- dose cohorts. Approximately 330 patients were 
planned to be enrolled in phase IB in the nine disease- 
specific cohorts.
study population
Patients (aged ≥18 years) with previously treated histo-
logically/cytologically confirmed advanced solid tumors 
with measurable disease (as defined by Response Evalua-
tion Criteria in Solid Tumors (RECIST) V.1.1 criteria), an 
Eastern Cooperative Oncology Group performance status 
≤1 and adequate organ function, were eligible for enroll-
ment. Patients with previously treated brain metastases 
that was/were asymptomatic and radiographically stable 
and not requiring steroid medications for 4 weeks prior 
to enrollment were also eligible. Patients who received 
prior anti- PD-1/PD- L1 treatments; had a history of hyper-
sensitivity reactions to monoclonal antibodies; a history 
of, or active, autoimmune disease; a history of interstitial 
lung disease or non- infectious pneumonitis, except for 
radiation- induced cases; a prior malignancy within the 
previous 2 years except for locally curable cancers that 
have apparently been cured (eg, basal or squamous cell 
skin cancer, superficial bladder cancer or carcinoma in 
situ of the cervix or breast cancer); patients who had 
prior liver transplant, allogeneic organ transplantation 
or bone marrow transplant and patients with a require-
ment for systemic treatment with corticosteroids (<10 mg 
daily prednisone equivalents) or other immunosuppres-
sive medications within 2 weeks of study drug adminis-
tration were excluded. PD- L1 expression was assessed 
retrospectively.
study objectives and assessments
The primary objectives of this study were to assess the 
safety and tolerability of tislelizumab (phase IA) as well 
as antitumor response (phase IB). Secondary objectives 
included determining the MTD and the optimal dose and 
treatment regimen, characterization of the tislelizumab 
PK profile and assessment of host immunogenicity to 
tislelizumab; assessment of confirmed ORR by PD- L1 
status was exploratory.
Safety/tolerability was assessed across the entire study 
and included continuous monitoring of AEs, as well as 
vital signs, physical examinations, electrocardiograms and 
laboratory investigations at specific study visits. AEs were 
4 Desai J, et al. J Immunother Cancer 2020;8:e000453. doi:10.1136/jitc-2019-000453
Open access 
Ta
b
le
 2
 
S
um
m
ar
y 
of
 P
K
 p
ar
am
et
er
s 
of
 s
in
gl
e-
 ag
en
t 
tis
le
liz
um
ab
 fo
llo
w
in
g 
si
ng
le
- a
d
m
in
is
tr
at
io
n 
an
d
 m
ul
tip
le
- a
d
m
in
is
tr
at
io
n 
to
 p
at
ie
nt
s 
w
ith
 a
d
va
nc
ed
 t
um
or
s 
(P
K
 
an
al
ys
is
 s
et
)
D
o
se
 le
ve
l
N
C
yc
le
 1
C
yc
le
 4
 o
r 
cy
cl
e 
5
t 1
/2
 (d
ay
)†
C
m
ax
 (μ
g
/m
L)
t m
ax
 (h
o
ur
)
A
U
C
ta
u*
 (μ
g
/
m
L*
d
ay
)
A
U
C
0-
 in
f (
μg
 /
m
L*
d
ay
)
N
C
m
ax
 (μ
g
/m
L)
t m
ax
 (h
o
ur
)
A
U
C
ta
u*
(μ
g
/m
L*
d
ay
)
D
os
e 
es
ca
la
tio
n 
(p
ar
t 
1)
 
 0.
5 
m
g/
kg
 e
ve
ry
 2
 w
ee
ks
3
13
.5
±
3.
80
3.
46
±
3.
12
84
.9
2±
35
.9
0
14
7.
9±
94
.4
2
3
23
.1
±
11
.4
2.
76
±
3.
24
17
8.
6±
10
2.
6
10
.7
±
3.
90
 
 2 
m
g/
kg
 e
ve
ry
 2
 w
ee
ks
6
48
.3
±
6.
89
2.
39
±
0.
89
33
2.
2±
57
.3
3
61
3.
6±
10
7.
2
4
12
2±
25
.1
2.
71
±
2.
59
10
94
±
38
8.
2
12
.9
±
1.
20
 
 5 
m
g/
kg
 e
ve
ry
 2
 w
ee
ks
6
14
7±
50
.8
2.
48
±
0.
73
81
1.
8±
23
9.
5
17
34
±
12
65
3
20
5±
59
.9
1.
40
±
0.
63
16
82
±
74
6.
2
15
.0
±
14
.4
 
 10
 m
g/
kg
 e
ve
ry
 2
 w
ee
ks
6
27
8±
53
.7
2.
43
±
1.
83
19
16
±
45
8.
5
37
77
±
10
20
1
47
6
0.
75
34
53
14
.5
±
4.
04
S
ch
ed
ul
e 
ex
p
an
si
on
 (p
ar
t 
2)
 
 2 
m
g/
kg
 e
ve
ry
 2
 w
ee
ks
18
47
.7
±
10
.6
1.
85
±
0.
69
35
0.
9±
87
.9
4
72
3.
7±
29
1.
0
—
—
—
—
14
.1
±
4.
42
 
 2 
m
g/
kg
 e
ve
ry
 3
 w
ee
ks
18
56
.8
±
12
.8
1.
57
±
0.
65
51
2.
1±
12
2.
2
93
3.
1±
49
7.
6
—
—
—
—
17
.1
±
8.
14
 
 5 
m
g/
kg
 e
ve
ry
 2
 w
ee
ks
17
13
3±
31
.4
1.
73
±
0.
40
87
5.
9±
24
0.
7
17
24
±
68
9.
4
1
36
0
0.
72
26
79
13
.9
±
4.
88
 
 5 
m
g/
kg
 e
ve
ry
 3
 w
ee
ks
20
13
0±
29
.7
4.
95
±
15
.4
12
19
±
28
7.
4
22
70
±
79
0.
4
—
—
—
—
19
.6
±
7.
63
Fi
xe
d
 d
os
e 
(p
ar
t 
3)
 
 20
0 
m
g 
ev
er
y 
3 
w
ee
ks
12
77
.2
±
13
.9
1.
40
±
0.
82
67
4.
7±
17
3.
6
11
72
±
39
3.
8
5
90
.9
±
16
.9
0.
78
±
0.
19
97
7.
8±
44
0.
3
16
.8
±
5.
50
*T
au
 w
as
 d
efi
ne
d
 a
s 
14
 d
ay
s 
fo
r 
ev
er
y 
2 
w
ee
ks
 a
nd
 2
1 
d
ay
s 
fo
r 
ev
er
y 
3 
w
ee
ks
; c
yc
le
: 2
8 
d
ay
s 
p
er
 c
yc
le
 fo
r 
ev
er
y 
2 
w
ee
ks
; 2
1 
d
ay
s 
p
er
 c
yc
le
 fo
r 
ev
er
y 
3 
w
ee
ks
.
†C
al
cu
la
te
d
 fr
om
 c
yc
le
 1
 d
at
a.
A
U
C
0-
 in
f, 
ar
ea
 u
nd
er
 c
ur
ve
 fr
om
 t
im
e 
ze
ro
 t
o 
in
fin
ity
; A
U
C
ta
u,
 a
re
a 
un
d
er
 c
ur
ve
 w
ith
in
 t
he
 d
os
in
g 
in
te
rv
al
; C
m
ax
, o
b
se
rv
ed
 m
ax
im
um
 c
on
ce
nt
ra
tio
n;
 P
K
, p
ha
rm
ac
ok
in
et
ic
; t
½
, t
er
m
in
al
 h
al
f-
 lif
e 
fo
llo
w
in
g 
th
e 
fir
st
 d
os
e;
 t
m
ax
, t
im
e 
to
 o
b
se
rv
ed
 m
ax
im
um
 c
on
ce
nt
ra
tio
n.
5Desai J, et al. J Immunother Cancer 2020;8:e000453. doi:10.1136/jitc-2019-000453
Open access
Figure 2 Concentration of tislelizumab following a single 200 mg dose vs single 2 and 5 mg dose.
categorized according to severity (NCI- CTCAE V.4.03), 
seriousness and relationship to the study treatment. Anti-
tumor activity was assessed by CT imaging at screening, 
every 8 (every 2 weeks) or 9 (every 3 weeks) weeks for the 
first 12 months, and every 12 weeks thereafter. Tumor 
response was evaluated by RECIST V.1.1 criteria13 for all 
tumor types. Formalin- fixed, paraffin- embedded tumor 
tissue from biopsies and resections collected before tisleli-
zumab treatment were used for PD- L1 analysis by immu-
nohistochemistry with the VENTANA PD- L1 (SP263) 
Assay (Ventana Medical Systems, Tucson, Arizona, USA). 
Definition of PD- L1 positivity was different for individual 
tumor types based on previously reported cut- offs. The 
rationale of cut- off selection for each indication was based 
on published PD- L1 algorithms. PD- L1 expression was 
scored as: 1) the percentage of tumor cells (TC) with any 
membrane staining; the percentage of tumor- associated 
immune cells (IC) with staining at any intensity or 3) the 
percentage of tumor area occupied by tumor- associated 
IC (TC/IC) with staining at any intensity (see online 
supplementary appendix, p3).
Standard PK parameters (eg, area under the 
concentration- time curve (AUC), maximal plasma 
concentration (Cmax) and time to maximal plasma 
concentration) were estimated. As an indication of target 
engagement, PD-1 receptor occupancy assay was centrally 
assessed on samples taken from select patients enrolled 
in arm 2 in phase IB. Immunogenic responses to tisleli-
zumab were assessed for antidrug antibody (ADA) forma-
tion. Blood samples for PK, receptor occupancy and 
immunogenicity assessment were collected as described 
below.
In part 1, cycles 1 and 4, predose (within 1 hour before 
administration) and postdose (0.5, 1.5, 6, 24, 72 (or 
96), 168 and 336 hours after the end of infusion) blood 
samples were collected on days 1, 2, 4 (or 5), 8 and 15 to 
assess the PK profile of tislelizumab. For additional cycles, 
blood samples were collected on day 1 of each cycle at 
the following time points: predose (within 1 hour before 
administration) and postdose (end infusion to 30 min). In 
part 2, predose (within 60 min before the start of infusion) 
and postdose (within 30 min after the end of infusion) 
samples were collected at cycle 1 day 1 and day 15 (only 
for every 2 weeks), day 1 of cycle 2, every subsequent cycle 
in the first 12 months and approximately every 6 months 
thereafter. Additional PK samples were collected at cycle 
1 day 4 (or 5), day 8, day 15 (only for every 3 weeks) and 
at the mandatory safety follow- up visit. In part 3, predose 
(trough, within 24 hours before the start of infusion) 
and postdose (within 30 min after the end of infusion) 
samples were collected on day 1 of cycle 1, cycle 2, cycle 
3, cycle 5 and every two cycles in first 6 months, every four 
cycles in the next 6 months and approximately every 6 
months thereafter. Additional PK samples were collected 
at day 2, day 4 (or 5), day 8 and day 15 of cycle 1 and cycle 
5; a predose sample was also collected on cycle 5 day 22 
(cycle 6 day 1). Further PK samples were collected at the 
mandatory safety follow- up visit.
For subjects in phase IA part 1, blood samples for 
immunogenic analysis were collected before starting the 
day 1 infusion every cycle in the first 6 months, every 
two cycles in the next 6 months, approximately every 6 
months thereafter and at the mandatory safety follow- up 
visit. For subjects in phase IA part 2, blood samples were 
collected within 24 hours before starting the day 1 infu-
sion every cycle in the first 6 months, every two cycles 
(every 2 weeks) or three cycles (every 3 weeks) in the 
next 6 months, approximately every 6 months thereafter 
and at the mandatory safety follow- up visit. For subjects 
in phase IA part 3, blood samples were collected before 
starting the day 1 infusion every two cycles in the first 6 
months, every four cycles in the next 6 months, approx-
imately every 6 months thereafter and at the mandatory 
safety follow- up visit. For subjects in phase IB, blood 
samples were collected before starting the day 1 infusion 
of cycle 1 and every two cycles in the first 6 months, every 
four cycles in the next 6 months, approximately every 6 
months thereafter and at the mandatory safety follow- up 
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Table 3 Treatment- emergent adverse events* (SAF; n=451)
Preferred term
Total (n=451)
Grade 1–2 Grade 3 Grade 4 Grade 5
Fatigue 120 (26.6) 8 (1.8) 0 0
Nausea 106 (23.5) 6 (1.3) 0 0
Decreased appetite 92 (20.4) 0 0 0
Constipation 76 (16.9) 3 (0.7) 0 0
Diarrhea 75 (16.4) 8 (1.8) 0 0
Abdominal pain 62 (13.7) 7 (1.6) 0 0
Cough 62 (13.7) 0 0 0
Back pain 61 (13.5) 6 (1.3) 0 0
Rash 60 (13.3) 1 (0.2) 0 0
Vomiting 58 (12.9) 8 (1.8) 0 0
Dyspnea 43 (9.5) 2 (0.4) 0 0
Weight decreased 37 (8.2) 3 (0.7) 0 0
Hypercalcemia 19 (4.2) 3 (0.7) 0 0
Anemia 19 (4.2) 22 (4.9) 0 0
Increased ALT 17 (3.8) 8 (1.8) 0 0
Increased AST 16 (3.5) 7 (1.5) 0 0
Lower respiratory 
tract infection
12 (2.7) 3 (0.7) 0 0
Hypokalemia 12 (2.7) 8 (1.8) 1 (0.2) 0
Dysphagia 9 (2.0) 7 (1.6) 0 0
Pneumonia 7 (1.6) 20 (4.4) 0 3 (0.7)
Pleural effusion 7 (1.6) 5 (1.1) 0 1 (0.2)
Pneumonitis 6 (1.3) 6 (1.3) 0 1 (0.2)
Hypertension 6 (1.3) 6 (1.3) 0 0
Ascites 6 (1.3) 7 (1.6) 0 0
Hyponatremia 5 (1.1) 3 (0.7) 0 0
Increased blood 
bilirubin
4 (0.9) 2 (0.4) 1 (0.2) 0
Colitis 3 (0.7) 3 (0.7) 0 0
Hyperglycemia 1 (0.2) 4 (0.9) 1 (0.2) 0
Pulmonary 
embolism
0 5 (1.1) 0 0
Upper 
gastrointestinal 
hemorrhage
0 4 (0.9) 0 0
Small intestinal 
obstruction
0 3 (0.7) 0 0
Sepsis 0 1 (0.2) 2 (0.4) 1 (0.2)
Data presented as n (%).
*This table shows all grade 1 or 2 adverse events occurring in ≥10% of 
patients and grade 3–5 events occurring in three or more patients.
ALT, alanine aminotransferase; AST, aspartate aminotransferase; SAF, 
safety analysis set.
visit. The immunogenicity results were summarized using 
descriptive statistics by the number and percentage of 
patients who developed detectable ADA. The incidence 
of positive ADA and neutralizing ADA is reported for 
patients in the ADA analysis set.
For select patients in arm 2 in phase IB, blood samples 
for receptor occupancy assessment were taken on cycle 
1 day 1 (predose) and day 2 (approximately 24 hours 
after the first dose) as well as predose on day 1 of cycles 
2 and 3.
statistical analyses
SAS V.9.4 was used for statistical analyses. Descriptive statis-
tics were used to summarize all study data. The Kaplan- 
Meier method estimated median time and 95% CI for 
progression- free survival (PFS) and overall survival (OS). 
The safety/tolerability profile and antitumor activity of 
tislelizumab were assessed in the safety analysis set (SAF; 
patients who received at least one dose of tislelizumab); 
DLTs were determined from the DLT set (patients who 
experienced a DLT during cycle 1 and received at least 
90% of the planned doses during the DLT observation 
period (cycle 1)) and the PK profile was established from 
the PK analysis set (patients who had received at least the 
first dose of tislelizumab and provided PK samples as per 
protocol following first dosing).
results
Population disposition, demographics and disease baseline 
characteristics
Between May 2015 and October 2017, 27 sites in 
Australia, Korea, New Zealand and Taiwan enrolled 451 
patients (phase IA, n=116; phase IB, n=335) (see online 
supplementary figure S1). In phase IA part 1, 22 patients 
received one of four escalating doses of tislelizumab every 
2 weeks (0.5 mg/kg (n=3), 2 mg/kg (n=6), 5 mg/kg (n=6) 
and 10 mg/kg (n=7)). In part 2, 81 patients were treated 
with tislelizumab (2 mg/kg every 2 weeks (n=20), 5 mg/
kg every 2 weeks (n=20), 2 mg/kg every 3 weeks (n=21) 
and 5 mg/kg every 3 weeks (n=20)). In part 3, 13 patients 
were treated with fixed- dose tislelizumab (200 mg every 
3 weeks). All 335 patients enrolled in phase IB received 
tislelizumab 5 mg/kg every 3 weeks.
Median age of all enrolled patients was 61.0 years (range: 
18–81) with more male than female patients (table 1). 
This was a heavily pretreated population with >95% of 
patients having received ≥1 prior anticancer drug treat-
ments, including platinum compounds (66.1%), pyrim-
idine analogs (50.6%), taxanes (38.8%), anthracyclines 
(25.9%) and protein kinase inhibitors (17.5%).
The median treatment duration of tislelizumab was 2.8 
months (range: 0.13–43.7); 65 patients (14.4%) received 
tislelizumab for ≥12 months. The median duration of 
study follow- up was 8.6 months (range: 0.1–40.8) in all 
patients: 13.6 months (range: 0.7, 40.8) in phase IA and 
7.6 months (0.1–35.9) in phase IB. Of the 451 enrolled 
patients, 123 (27.3%) experienced ≥1 AE leading to dose 
modification (ie, treatment interruption or dose delay). 
Overall, infusion- related reactions (n=12; 2.7%) was the 
most common AE leading to dose modification (see 
online supplementary table S1). Treatment with tisleli-
zumab was discontinued in 24 patients (5.3%) due to 
7Desai J, et al. J Immunother Cancer 2020;8:e000453. doi:10.1136/jitc-2019-000453
Open access
Table 4 Clinical response as assessed by investigator by phase and overall (SAF)
Phase IA
(n=116)
Phase IB
(n=335)
Overall
(n=451)
ORR (CR, PR)
  % (95% CI) 18.1 (11.57 to 26.33) 11.6 (8.41 to 15.57) 13.3 (10.31 to 16.79)
Best overall confirmed response, n (%)
  CR 4 (3.4) 2 (0.6) 6 (1.3)
  PR 17 (14.7) 37 (11.0) 54 (12.0)
  SD 42 (36.2) 99 (29.6) 141 (31.3)
  PD 48 (41.4) 152 (45.4) 200 (44.3)
  NE 1 (0.9) 6 (1.8) 7 (1.6)
  Missing 4 (3.4) 39 (11.6) 43 (9.5)
DCR (CR, PR, SD)
  n (%) 63 (54.3) 138 (41.2) 201 (44.6)
  Exact 95% CI 44.81 to 63.59 35.87 to 46.67 39.92 to 49.29
CBR (CR, PR, durable SD*)
  n (%) 35 (30.2) 82 (24.5) 117 (25.9)
  Exact 95% CI 22.00 to 39.39 19.97 to 29.45 21.96 to 30.25
Time to response (months)
  N 21 39 60
  Median (range) 2.2 (1.8 to 15.9) 2.2 (1.3 to 10.2) 2.2 (1.3 to 15.9)
*Durable SD is defined as SD with duration ≥24 weeks.
CBR, clinical benefit rate; CR, complete response; DCR, disease control rate; NE, not estimable; ORR, objective response rate; PD, 
progressive disease; PR, partial response; SAF, safety analysis set; SD, stable disease.
tislelizumab- related AEs, most commonly due to pneu-
monitis (n=8; 1.8%). One DLT was observed during dose 
escalation (grade 3 colitis in the 5 mg/kg every 2 weeks 
cohort); the maximum administered dose was 10 mg/kg 
every 2 weeks.
Pharmacokinetic profile of tislelizumab
The single- dose and multiple- dose PK profiles of tisleli-
zumab were characterized from 109 patients from phase 
IA (table 2). Mean steady- state PK profiles for the every 2 
weeks and every 3 weeks dosing regimens are presented in 
online supplementary figure S2. Drug exposure (Cmax and 
AUC0–14) increased in a dose- proportional manner from 
0.5 to 10 mg/kg tislelizumab; no correlation was reported 
between clearance and baseline body weight, supporting 
fixed dosing of tislelizumab. At the 5 mg/kg dose, PD-1 
receptor occupancy was >90%.
Data from the 200 mg every 3 weeks cohort demon-
strated that tislelizumab concentrations after the first dose 
fell within 2 and 5 mg/kg dose range (figure 2). Tisleli-
zumab demonstrated a 1.69- fold accumulation ratio, 
which was consistent with the estimated terminal half- life 
following tislelizumab 200 mg every 3 weeks (t1/2=16.8±5.5 
days). Steady- state trough concentrations from patients 
with various tumor types in phase IB generally fell within 
a similar range of concentrations (see online supplemen-
tary figure S3), suggesting the tislelizumab PK profile is 
independent of tumor type.
tislelizumab safety/tolerability profile
Of the 451 enrolled patients, 436 (96.7%) experienced 
≥1 AE. Safety/tolerability profiles were generally consis-
tent across study phases as well as dose levels and sched-
ules (see online supplementary tables S2–3). Commonly 
reported grade 1–2 AEs included fatigue, nausea and 
decreased appetite (table 3). Fatigue was the only AE 
considered related to treatment in ≥10% of the total popu-
lation (13.1%), and was the most commonly reported 
tislelizumab- related AE (TRAE) across doses and sched-
ules (see online supplementary tables S4 and S5). Poten-
tial irAEs occurred in 35.0% of patients; irAEs occurring 
in ≥5% of patients were rash (all terms; 14.6%), diarrhea 
(6.9%) and hypothyroidism (6.0%). The emergence of 
ADAs occurred in 18.7% of patients across both phases, 
with one patient (0.3%) testing positive for neutralizing 
antibodies.
AEs of grade 3–4 severity, regardless of attribution, 
were reported in 198 patients (43.9%); these AEs were 
consistently reported across both phases. Grade 3–4 AEs 
occurring in ≥2% of patients included anemia (n=22; 
4.9%), pneumonia (n=21; 4.7%) and hypokalemia (n=9; 
2.0%). Thirty- nine patients (8.6%) experienced a grade 
3–4 TRAE; increased alanine aminotransferase (n=6; 
1.3%), pneumonitis (n=5; 1.1%), increased aspartate 
aminotransferase (n=4; 0.9%), colitis (n=3; 0.7%), diar-
rhea (n=3; 0.7%) and fatigue (n=3; 0.7%) were TRAEs of 
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grade 3–4 occurring in >2 patients. Serious AEs consid-
ered related to tislelizumab were reported in 35 (7.8%) 
patients. Pneumonitis (n=8; 1.8%) and colitis (n=5; 
1.1%) were the only serious AEs related to tislelizumab 
reported in ≥5 patients. Overall, 14 patients (3.1%) expe-
rienced a fatal AE. Two patients experienced fatal TRAEs 
(pneumonitis, n=1; fulminant hepatitis, n=1); both AEs 
were considered potentially immune- related and both 
cases were complicated by underlying disease. The pneu-
monitis event occurred in a patient with NSCLC with 
compromised pulmonary capacity at baseline; the hepa-
titis event occurred in a patient with hepatocellular carci-
noma (HCC) with rapidly progressing disease.
Antitumor activity of tislelizumab
Confirmed responses were observed across phases 
(table 4) and dose/dosing schedules (see online supple-
mentary table S6). Overall, the confirmed ORR was 13.3% 
(95% CI: 10.31 to 16.79) (table 4). While responses were 
primarily driven by patients who achieved partial response 
(PR; n=54; 12.0%), six patients achieved complete 
response (CR; 1.3%) in esophageal cancer, clear cell 
carcinoma of the endometrium, Merkel cell carcinoma, 
cutaneous squamous cell carcinoma, renal cell carcinoma 
and urothelial carcinoma (n=1 each). The overall disease 
control (CR+PR+stable disease (SD)) and clinical benefit 
(CR+PR+SD ≥24 weeks) rates were 44.6% and 25.9%, 
respectively. The median duration of response (DoR) was 
16.0 months (95% CI: 11.1 to 25.6). Median DoR was 14.6 
months (95% CI: 8.3 to not estimable (NE)) in phase IA 
and 16 months (95% CI: 9.2 to NE) in phase IB.
When responses per tumor type were evaluated by 
PD- L1 status using previously published cut- offs, there 
was a trend of higher ORRs in PD- L1- positive (PD- L1+) 
patients with HCC, as well as gastric, esophageal, ovarian, 
non- small cell lung, colorectal, head and neck squamous 
cell and urothelial cancers (table 5). Notably, all patients 
in the HCC cohort who responded to tislelizumab were 
PD- L1+ (ORR=23.1%). In patients with renal carcinoma, 
ORR was identical between PD- L1+ and PD- L1− groups 
(33.3% vs 33.3%). No patients from the triple- negative 
breast cancer or cholangiocarcinoma cohorts responded 
to treatment, and thus the impact of PD- L1 status could 
not be assessed.
estimated survival associated with tislelizumab treatment
As of the data cut- off of May 20, 2019, 58.3% of patients 
with an objective response had progressed or died. 
Median OS across the study was 10.3 months (95% CI: 
8.5 to 11.6); median OS was 13.6 months (95% CI: 9.9 
to 17.5) and 9.3 months (95% CI: 7.7 to 11.1) in phases 
IA and IB, respectively (see online supplementary figure 
S4A). Overall survival rates at 6 and 12 months were 67.3% 
(95% CI: 62.7 to 71.6) and 43.1% (95% CI: 38.3 to 47.8), 
respectively. Across the study, median PFS was 2.1 months 
(95% CI: 2.1 to 2.7), with a median PFS of 3.5 months 
(95% CI: 2.1 to 3.8) in phase IA and 2.1 months (95% CI: 
2.1 to 2.2) in phase IB. The proportion of patients with 
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PFS at 6 and 12 months was 29.5% (95% CI: 25.2 to 33.8) 
and 15.6% (95% CI: 12.3 to 19.2), respectively (see online 
supplementary figure S4B).
dIsCussIon
This phase IA/IB study was conducted to characterize the 
safety/tolerability, PK and preliminary antitumor activity 
of tislelizumab monotherapy. Across the 451 patients 
enrolled from Australia, Korea, New Zealand and Taiwan, 
tislelizumab was generally well tolerated with a safety/
tolerability profile consistent with other anti- PD-1 anti-
bodies.10 14–19 The majority of tislelizumab- related AEs 
observed in this study were grade 1–2 in severity; 9% of 
patients had grade ≥3 AEs considered possibly related to 
tislelizumab. irAEs were reported in 35% of patients; rash 
was the only reported irAE with an incidence of >10%. 
Severe and fatal treatment- related AEs were uncommon. 
Clinical responses were observed across multiple solid 
tumors. These responses were durable, with a median 
duration of 16 months.
A key study objective was to determine the appropriate 
dosing for future clinical studies. Ultimately, a fixed 
200 mg dose of tislelizumab every 3 weeks was selected 
for further evaluation based on comparable safety, PK 
and efficacy profiles between the 200 mg fixed- dose and 
the 2 and 5 mg/kg weight- based doses. One DLT was 
observed (grade 3 colitis) in the 5 mg/kg every 2 weeks 
cohort. No clear dose- related safety/tolerability concerns 
were observed between patients receiving 2 and 5 mg/
kg every 2 weeks and every 3 weeks, and no unexpected 
tislelizumab- related AEs occurred in the 200 mg fixed- 
dose cohort compared with body weight- based cohorts, 
and the practicalities provided by fixed dosing. Addition-
ally, tislelizumab clearance was found to be independent 
of body weight, ethnicity and sex; observed exposure of 
a 200 mg dose fell within the bounds of serum exposure 
observed after 2 and 5 mg/kg doses. Finally, ORRs in 
patients treated with tislelizumab 2 and 5 mg/kg every 2 
weeks ranged between 10% and 15%, compared with a 
range of 15%–38% for patients treated at 2 and 5 mg/kg 
every 3 weeks. Of the evaluable patients treated at 200 mg 
every 3 weeks (n=13), three (23%) had achieved partial 
response, consistent with results seen with the weight- 
based cohorts.
As these data are from a non- randomized, open- label 
study, the data have some inherent limitations. Response 
and survival of tislelizumab were assessed in a heteroge-
neous group of patients with a variety of advanced solid 
tumors with different levels and patterns of PD- L1 expres-
sion. Patients with PD- L1− tumors achieved objective 
responses, suggesting that PD- L1 expression, as a single 
biomarker for response, may not be sufficient to iden-
tify those who are more likely to respond to checkpoint 
inhibition. It is important to note that key differences in 
PD- L1 antibody clones and various immunohistochem-
ical platforms have raised questions about comparability. 
In terms of assessment of PD- L1 expression, specific 
tumor- type cutoffs vary depending on the antibody 
clone used. As different anti- PD- L1 antibody clones can 
have different levels of sensitivity and specificity, and can 
recognize different epitopes, using the same cut- off for 
different clones may cause results to be skewed, leading 
to an inappropriate treatment selection. Finally, the 
clinical impact of tislelizumab’s lack of binding to FcγRI 
compared with other anti- PD1 antibodies was difficult to 
determine in this phase IA/IB trial. Additional studies 
are needed to enhance our understanding of the tumor 
microenvironment and the effects of anti- PD-1 antibodies 
and further evaluation of tislelizumab in specific tumor 
types will provide a more accurate assessment of its anti-
tumor activity.
In this study, single- agent tislelizumab demonstrated a 
favorable safety/tolerability profile and induced durable 
clinical responses in ≥10% of patients, which is prom-
ising in this heavily pretreated population, including 
a balanced population of both Caucasian and Asian 
patients. Furthermore, these responses were observed in 
patients with either PD- L1+ or PD- L1− tumors; additional 
studies are needed to further characterize the predictive 
value of PD- L1, and optimize a diagnostic/treatment algo-
rithm for different tumor types. Based on the strength 
of these data, tislelizumab is currently being evaluated as 
monotherapy and in combination therapy for the treat-
ment of solid tumors and hematological malignancies, 
including in registrational studies in esophageal, gastric, 
HCC, lung and urothelial cancers.
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